Risk of acute kidney injury associated with the use of fluoroquinolones

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 10, 2013, Pages

  Bird, Steven T ^a,b   Etminan, Mahyar ^c   Brophy, James M ^d   Hartzema, Abraham G ^b   Delaney, Joseph A C ^b,e  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; AZITHROMYCIN; CIPROFLOXACIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLONE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE INFECTION; CASE CONTROL STUDY; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG POTENTIATION; DRUG USE; GASTROINTESTINAL INFECTION; HUMAN; INFECTIOUS ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRESCRIPTION; QUANTITATIVE ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; RISK FACTOR; SKIN INFECTION; TIME SERIES ANALYSIS; TREATMENT INDICATION; UNITED STATES; URETHRITIS; UROGENITAL TRACT INFECTION;

EID: 84880034433     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121730     Document Type: Article

References (39)

1. Linder JA, Huang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995-2002. Am J Med 2005;118:259-68. (Pubitemid 40312637)
2. Ciprofloxacin [package insert]. Schaumberg, IL: SAGENT Pharmaceuticals; 2011.
3. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
4. Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture. N Engl J Med 2995;332:193.
5. Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA 2012;307:1414-9.
6. Lomaestro BM. Fluoroquinolone-induced kidney injury. Drug Saf 2000;22:479-85.
7. Health IMS. LifeLink Health Plan Claims Database: overview and study design issues . Little Rock (AK): University of Arkansas for Medical Sciences; 2010. Available: www.uams .edu/TRI /hsrcore/Lifelink-Health-Plan-Claims-Data- DesignIssues-wcost-April2010[1].pdf (accessed 2013 Feb. 28).
8. Bird ST, Hartzema AG, Brophy JM, et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 2013;185:E115-20.
9. Etminan M, Delaney JA, Bressler B, et al. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011;183:899-904.
10. Bird ST, Pepe SR, Etminan M, et al. The association between drospirenone and hyperkalemia: a comparative-safety study. BMC Clin Pharmacol 2011;11:23.
11. Wald R, Liangos O, Waikar SS, et al. The identification of patients with acute renal failure (ARF) using administrative data: a validation study [abstract]. J Am Soc Nephrol 2005;16:F-PO1031.
12. Jurralink D, Preyra C, Croxford R. Canadian Institute for Health Information Discharge Abstract Database: a validation study. Toronto (ON): Institute for Clinical Evaluative Sciences; 2006.
13. Parker JP, Li Z, Damberg CL, et al. Administrative versus clinical data for coronary artery bypass graft surgery report cards: the view from California. Med Care 2006;44:687-95. (Pubitemid 44284283)
14. Geraci JM, Ashton CM, Kuykendall DH, et al. International Classification of Diseases, 9th revision, clinical modification codes in discharge abstracts are poor measures of complication occurrence in medical inpatients. Med Care 1997;35:589-602. (Pubitemid 127455084)
15. Quan H, Parsons GA, Ghali WA. Assessing accuracy of diagnosis-type indicators for flagging complications in administrative data. J Clin Epidemiol 2004;57:366-72. (Pubitemid 38609275)
16. So L, Evans D, Quan H. ICD-10 coding algorithms for defining comorbidities of acute myocardial infarction. BMC Health Serv Res 2006;6:161.
17. Waikar SS, Wald R, Chertow GM, et al. Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 2006;17:1688-94. (Pubitemid 43794671)
18. Waikar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006;17:1143-50.
19. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-6. (Pubitemid 34454211)
20. Liangos O, Wald R, O'Bell JW, et al. Epidemiology and outcomes of AKI in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006;1:43-51.
21. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008;168:329-35. (Pubitemid 352019783)
22. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol 1990;19:205-13. (Pubitemid 20126858)
23. Mansoor GA, Panner BJ, Ornt DB. Azithromycin-induced acute interstitial nephritis. Ann Intern Med 1993;119:636-7.
24. Soni N, Harrington JW, Weiss R, et al. Recurrent acute interstitial nephritis induced by azithromycin. Pediatr Infect Dis J 2004;23:965-6. (Pubitemid 40812789)
25. Appel GB, Garvey G, Silva F, et al. Acute interstitial nephritis due to amoxicillin therapy. Nephron 1981;27:313-5. (Pubitemid 11072578)
26. Ferrara P, D'Aleo CM, Rigante D, et al. Amoxicillin-induced nephritis and tubulitis in a child. Urol Int 2003;71:124-6. (Pubitemid 36829148)
27. Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res 2009;18:53-65.
28. Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 1997;6(Suppl 3):S51-9. (Pubitemid 27483541)
29. Lim S, Alam MG. Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia. Ren Fail 2003;25:647-51. (Pubitemid 36944745)
30. Bailey JR, Trott SA, Philbrick JT. Ciprofloxacin-induced acute interstitial nephritis. Am J Nephrol 1992;12:271-3. (Pubitemid 23010400)
31. Lien YH, Hansen R, Kern WF, et al. Ciprofloxacin-induced granulomatous interstitial nephritis and localized elastolysis. Am J Kidney Dis 1993;22:598-602. (Pubitemid 23308973)
32. Ramalakshmi S, Bastacky S, Johnson JP. Levofloxacin-induced granulomatour interstitial nephritis. Am J Kidney Dis 2003;41:E7.
33. Thorsteinsson SB, Bergan T, Oddsdottir S, et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 1986;32:408-17. (Pubitemid 16044293)
34. Chopra N, Fine PL, Price B, et al. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol 2000;164:438. (Pubitemid 30481944)
35. Sedlacek M, Suriawinata AA, Schoolwerth A, et al. Ciprofloxacin crystal nephropathy - a "new" cause of AKI. Nephrol Dial Transplant 2006;21:2339-40. (Pubitemid 44295076)
36. Dichiara AJ, Atkinson M, Goodman Z, et al. Ciprofloxacin-induced acute cholestatic liver injury and associated kidney injury. Case report and review. Minerva Gastroenterol Dietol 2008;54:307-15.
37. Dharnidharka VR, Nadeau K, Cannon CL, et al. Ciprofloxacin overdose: AKI with prominent apoptotic changes. Am J Kidney Dis 1998;31:710-2.
38. Yew WW, Chau CH, Wong PC, et al. Ciprofloxacin induced renal dysfunction in patients with mycobacterial lung infections. Tuber Lung Dis 1995;76:173-5.
39. Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalemia and AKI: systematic review and meta-analysis. BMJ 2012;9:344:e42.